Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 11:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Standard IV administration of vancomycin Clear all
Completed Phase 2 Interventional Results available

Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

NCT00077675
View directory record Official record
Conditions
Infections, Gram-positive Bacterial
Interventions
Telavancin, vancomycin or antistaphylococcal penicillin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 6, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

NCT00061633
View directory record Official record
Conditions
Infections, Gram-Positive Bacterial, Abscess, Burns, Cellulitis, Ulcer, Wound Infections
Interventions
Telavancin, Vancomycin or antistaphylococcal penicillin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 6, 2026, 11:57 PM EDT
Completed Not applicable Interventional Results available

Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)

NCT01401023
View directory record Official record
Conditions
Diarrhea, Clostridium Difficile
Interventions
Tigecycline
Drug
Lead sponsor
Gary E. Stein, Pharm.D.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
East Lansing, Michigan • Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 6, 2026, 11:57 PM EDT
Recruiting Phase 4 Interventional

Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty

NCT06384651
View directory record Official record
Conditions
Infections, Ankle Arthritis
Interventions
Intraosseous Vancomycin Injection, Intravenous Vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 6, 2026, 11:57 PM EDT
Completed Not applicable Interventional

Clinical Decision Support Tool for Vancomycin Dosing in Children

NCT04911270
View directory record Official record
Conditions
Gram-Positive Bacterial Infections, Vancomycin, Pharmacokinetics, Pharmacodynamics
Interventions
Computer Decision Support Tool Intervention Group, Matched Historical Controls
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
Up to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 6, 2026, 11:57 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

NCT00711802
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
Daptomycin, Standard of Care (SOC)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
1 Year to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
22
States / cities
Birmingham, Alabama • Oakland, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 6, 2026, 11:57 PM EDT
Completed No phase listed Observational

Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection

NCT04317963
View directory record Official record
Conditions
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Interventions
Bezlotoxumab, Standard CDI treatment
Biological · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 6, 2026, 11:57 PM EDT
Terminated Phase 4 Interventional Results available

Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting

NCT01175707
View directory record Official record
Conditions
Complicated Skin or Skin Structure Infection
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Livonia, Michigan • Roseville, Minnesota • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 6, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Results available

Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci

NCT00428844
View directory record Official record
Conditions
Osteomyelitis
Interventions
daptomycin, vancomycin, teicoplanin, nafcillin, oxacillin, flucloxacillin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
17
States / cities
Little Rock, Arkansas • Englewood, Colorado • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 6, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Results available

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

NCT04775953
View directory record Official record
Conditions
Staphylococcal Bacteraemia
Interventions
Cefazolin, Dalbavancin, Daptomycin, Nafcillin, Oxacillin, Vancomycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Sacramento, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 6, 2026, 11:57 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Vancomycin in TKAs

NCT07282782
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Vancomycin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 6, 2026, 11:57 PM EDT
Completed Phase 4 Interventional Results available

Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol

NCT04042233
View directory record Official record
Conditions
Prosthetic Joint Infection, Vancomycin, Joint Diseases
Interventions
Experimental Intraosseous vancomycin 500mg in 250 mL NS, Standard IV administration of vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
19 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 6, 2026, 11:57 PM EDT
Recruiting Phase 3 Interventional

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2

NCT04678154
View directory record Official record
Conditions
Post Operative Surgical Site Infection
Interventions
Standard of care, Vancomycin and Tobramycin
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
31
States / cities
Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 6, 2026, 11:57 PM EDT
Terminated Phase 2 Interventional Results available

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

NCT02732327
View directory record Official record
Conditions
Neoplasms, Febrile Neutropenia
Interventions
CAZ-AVI, Vancomycin, Linezolid, Cefepime, Meropenem, Piperacillin/tazobactam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 6, 2026, 11:57 PM EDT
Not listed Phase 4 Interventional

IO vs IV Vancomycin in Tourniquetless TKA

NCT05705843
View directory record Official record
Conditions
Infection, Surgical Site
Interventions
Intraosseous Vancomycin Injection, Intravenous Vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
19 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 6, 2026, 11:57 PM EDT
Active, not recruiting Phase 2 Interventional

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

NCT04729322
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Biopsy, Fecal Microbiota Transplantation, Fecal Microbiota Transplantation Capsule, Metronidazole, Neomycin, Nivolumab, Pembrolizumab, Questionnaire Administration, Vancomycin
Procedure · Drug · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 6, 2026, 11:57 PM EDT
Active, not recruiting Phase 4 Interventional Results available

IO Vancomycin in TSA

NCT05831774
View directory record Official record
Conditions
Shoulder Injuries
Interventions
Intervention - Intraosseous (IO) administration of vancomycin, Control - Standard IV administration of vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 6, 2026, 11:57 PM EDT
Not listed Not applicable Interventional

Surgical Infection Rates With Adjunct Vancomycin Compared to Standard Peri-Operative IV Antibiotics

NCT02299882
View directory record Official record
Conditions
Lumbar Pain
Interventions
Vancomycin
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 6, 2026, 11:57 PM EDT
Not listed Not applicable Interventional

Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens

NCT02764359
View directory record Official record
Conditions
Infection, Sepsis, Obesity
Interventions
IV vancomycin
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 99 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 6, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Results available

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

NCT03485950
View directory record Official record
Conditions
Other Infectious Diseases
Interventions
Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 6, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Results available

Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

NCT03137173
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
ceftobiprole medocaril, vancomycin+aztreonam
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
16
States / cities
Anaheim, California • Chula Vista, California • Fresno, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Sep 6, 2026, 11:57 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

IO Vancomycin Spine

NCT06748144
View directory record Official record
Conditions
Lumbar Fusion Surgery
Interventions
Intraosseous Vancomycin, Intravenous Vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 6, 2026, 11:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

Intraosseous (IO) Cefazolin and Vancomycin in Primary Total Knee Arthroplasty (TKA)

NCT06640491
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
IO Administration of Cefazolin, IO Administration of Vancomycin, IV Administration of Cefazolin, IV Administration of Vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 6, 2026, 11:57 PM EDT